Solventum Corporation (SOLV)
- Previous Close
69.22 - Open
68.86 - Bid 67.88 x 800
- Ask 68.78 x 1100
- Day's Range
67.89 - 69.05 - 52 Week Range
47.16 - 73.40 - Volume
1,951,673 - Avg. Volume
1,407,101 - Market Cap (intraday)
11.762B - Beta (5Y Monthly) --
- PE Ratio (TTM)
29.10 - EPS (TTM)
2.34 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
63.25
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
www.solventum.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SOLV
View MorePerformance Overview: SOLV
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SOLV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SOLV
View MoreValuation Measures
Market Cap
11.96B
Enterprise Value
19.36B
Trailing P/E
29.59
Forward P/E
12.15
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.45
Price/Book (mrq)
4.17
Enterprise Value/Revenue
2.35
Enterprise Value/EBITDA
10.54
Financial Highlights
Profitability and Income Statement
Profit Margin
12.89%
Return on Assets (ttm)
6.78%
Return on Equity (ttm)
14.50%
Revenue (ttm)
8.21B
Net Income Avi to Common (ttm)
1.06B
Diluted EPS (ttm)
2.34
Balance Sheet and Cash Flow
Total Cash (mrq)
897M
Total Debt/Equity (mrq)
289.71%
Levered Free Cash Flow (ttm)
2.2B